Gallbladder Carcinoma — Clinical Trials

MONDO:000322043 active·18 recruitingLast updated: Mar 20, 2026, 7:42 AM

Trial Landscape

Gallbladder Carcinoma has an active clinical trial landscape, driven by drug treatment and procedure.

Recruiting

Active Trials

By Approach

Drug Treatment26

Procedure11

Biological Therapy4

Medical Device1

14 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Phase 1

Phase 2

Phase 3

18 trials are observational or have no phase designation.

Sponsor Types

Academic/Other36NIH4Industry2Collaborative Network1

Top Sponsors

Lisata Therapeutics, Inc.

Seagen, a wholly owned subsidiary of Pfizer

Trial Locations

United States14 trials

China12 trials

India3 trials

South Korea3 trials

Canada2 trials

Denmark2 trials

Germany2 trials

United Kingdom2 trials

Argentina1 trial

Bolivia1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

43 Trials

Phase 3Recruiting

NCT06712420

Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB)

Sponsor:Rajiv Gandhi Cancer Institute & Research Center, India

IndiaStarted: Jan 2025Est. completion: Dec 2028Updated: Apr 2025

Phase 2Recruiting

NCT07146646

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

Sponsor:Case Comprehensive Cancer Center

United StatesStarted: Dec 2025Est. completion: Apr 2027Updated: Feb 2026

Phase 2Recruiting

NCT04183712

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

Sponsor:Shanghai Jiao Tong University School of Medicine

ChinaStarted: Jun 2020Est. completion: Dec 2025Updated: Oct 2024

Phase 2Recruiting

NCT05833815

Addition of Everolimus to Standard of Care in Carcinoma Gallbladder

Sponsor:Banaras Hindu University

IndiaStarted: Nov 2022Est. completion: Dec 2024Updated: Aug 2024

Last updated over 18 months ago

Phase 2Recruiting

NCT06423170

A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs

Sponsor:Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

ChinaStarted: Jun 2023Est. completion: Dec 2026Updated: May 2024

Last updated over 18 months ago

Phase 2Recruiting

NCT05757336

Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer

Sponsor:Lu Wang, MD, PhD

ChinaStarted: Dec 2022Est. completion: Dec 2026Updated: Mar 2023

Last updated over 18 months ago

Phase 1Recruiting

NCT05285358

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

Sponsor:City of Hope Medical Center

United StatesStarted: Sep 2022Est. completion: Oct 2028Updated: Mar 2026

Not ApplicableRecruiting

NCT04907643

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Sponsor:Cedars-Sinai Medical Center

United StatesStarted: Oct 2021Est. completion: Mar 2027Updated: Feb 2026

Recruiting

NCT06192719

EULAT Eradicate GBC

Sponsor:Centre Paul Strauss

ArgentinaStarted: Dec 2019Est. completion: Dec 2028Updated: Feb 2026

Recruiting

NCT02012699

Integrated Cancer Repository for Cancer Research

Sponsor:University of Nebraska

United StatesStarted: Nov 2013Est. completion: Dec 2099Updated: Jan 2026

Phase 3Active, Not Recruiting

NCT02170090

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

Sponsor:Universitätsklinikum Hamburg-Eppendorf

AustraliaStarted: Apr 2014Est. completion: Dec 2025Updated: Mar 2025

Phase 2Active, Not Recruiting

NCT05564403

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Feb 2024Est. completion: May 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT02834013

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jan 2017Est. completion: May 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT04559139

Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer

Sponsor:ECOG-ACRIN Cancer Research Group

United StatesStarted: Feb 2021Est. completion: Jun 2029Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT04430738

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Sponsor:Seagen, a wholly owned subsidiary of Pfizer

United StatesStarted: Sep 2020Est. completion: Dec 2026Updated: Feb 2026

Phase 2Active, Not Recruiting

NCT02151084

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

Sponsor:University Health Network, Toronto

CanadaStarted: Nov 2014Est. completion: Sep 2026Updated: Dec 2025

Phase 2Active, Not Recruiting

NCT05712356

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Sponsor:Lisata Therapeutics, Inc.

United StatesStarted: Aug 2023Est. completion: Mar 2030Updated: Jun 2025

Phase 2Active, Not Recruiting

NCT04941287

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Dec 2021Est. completion: Apr 2026Updated: May 2025

Phase 2Active, Not Recruiting

NCT04308174

Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer

Sponsor:Asan Medical Center

South KoreaStarted: May 2020Est. completion: Dec 2025Updated: Jan 2025

Phase 2Active, Not Recruiting

NCT06717464

Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer

Sponsor:Tianjin Medical University Cancer Institute and Hospital

ChinaStarted: Nov 2024Est. completion: Dec 2027Updated: Dec 2024

Stay informed about clinical trials for Gallbladder Carcinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 20, 2026 at 7:42 AM

Gallbladder Carcinoma — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Top Sponsors

Trial Locations

43 Trials

Open Trials26

Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB)

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA

Addition of Everolimus to Standard of Care in Carcinoma Gallbladder

A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs

Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

EULAT Eradicate GBC

Integrated Cancer Repository for Cancer Research

Active Trials17

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer

Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer